PMID: 9182022Jan 1, 1997Paper

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer

Clinical Therapeutics
M BatesT Williamson

Abstract

A Markov model was developed to determine the cost of treating patients with stage IIIB or IV metastatic breast cancer with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) and dexrazoxane (administered after six courses of FAC) versus FAC alone. The primary end point in our economic study was cost per cardiac event avoided. Cost per life-year saved was also calculated, even though the survival advantage needs to be confirmed in follow-up studies. The model incorporated the direct medical costs of treating patients with chemotherapy, as well as the costs associated with treatment of any cardiac events that occurred. Data were collected for this analysis from several sources, including completed clinical trials on FAC plus dexrazoxane versus FAC plus placebo (obtained from two patient groups randomized at different time points), a panel of three oncologists, and a panel of three cardiologists. Analyses showed that therapy with dexrazoxane costs $5661.77 per cardiac event prevented. Sensitivity analyses on model variables were performed and showed that the basic results of the model did not change when parameters were varied. The clinical efficacy and cost-effectiveness of dexrazoxane as shown by the results of the current...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Jan 1, 1991·Medical Care·M S BakerR C Smucker
Mar 21, 1991·The New England Journal of Medicine·J H Doroshow
Oct 1, 1990·International Journal of Cardiology·L X FuA Hjalmarson
Jan 1, 1983·Medical Decision Making : an International Journal of the Society for Medical Decision Making·J R Beck, S G Pauker
Feb 1, 1982·Annals of Internal Medicine·S S LeghaE J Freireich
Jun 1, 1995·Risk Analysis : an Official Publication of the Society for Risk Analysis·T O TengsJ D Graham
Apr 1, 1994·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·B J O'BrienR Goeree
Jan 1, 1993·Cancer Treatment Reviews·R L Basser, M D Green
Jul 1, 1996·Annals of Internal Medicine·K ShanJ B Young
Jan 8, 1995·PharmacoEconomics·R Andrews, A J Cowley

❮ Previous
Next ❯

Citations

Aug 20, 2009·Cardiology in Review·Kuldeep Maradia, Maya Guglin
Dec 4, 2010·Cancer Treatment Reviews·Elżbieta Senkus, Jacek Jassem
Aug 7, 2009·The Breast : Official Journal of the European Society of Mastology·R C F LeonardS Oliveros
Feb 22, 2011·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·John J RasweilerKiranmayi V Mechineni
Jun 26, 2012·Molecular Ecology·Kritika M GargUma Ramakrishnan
Nov 4, 2004·Molecular Phylogenetics and Evolution·Polly CampbellThomas H Kunz
Oct 9, 2004·Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology·A Alwin Prem Anand, K Sripathi
Feb 19, 2005·Seminars in Oncology·Charles L Bennett, Elizabeth A Calhoun
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Sep 7, 2016·British Journal of Clinical Pharmacology·Kelley K HutchinsSteven E Lipshultz
Jan 13, 2016·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Quang A Le
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lynn M SchuchterUNKNOWN American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel
Jan 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MartyUNKNOWN Dexrazoxane Study Group
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Apr 25, 2020·Current Treatment Options in Oncology·Ariane Vieira Scarlatelli MacedoOtávio Rizzi Coelho-Filho
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robin L Jones

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the National Cancer Institute
Dawn L Hershman, Alfred I Neugut
Journal of the American College of Cardiology
Lynne E WagonerChristopher M O'Connor
Seminars in Oncology
C L Bennett, Elizabeth A Calhoun
© 2021 Meta ULC. All rights reserved